Impact of California's Medi-Cal Changes on Access to Weight Loss Drugs

In a significant policy shift, California's Governor Gavin Newsom has signed a budget that restricts Medi-Cal, the state's Medicaid program, from covering weight loss drugs like Wegovy and Zepbound unless prescribed for diabetes treatment. This decision is projected to save the state over $600 million by 2029, as officials argue that cutting this coverage promotes fiscal responsibility. However, critics, including health policy professor Kenneth Thorpe, contend that this move could ultimately lead to increased healthcare costs due to the long-term health risks associated with untreated obesity.

CalmattersCancer Risk Declines With Use of Ozempic and Zepbound– New Study Shows Weightloss Drugs Linked to ‘Reduced Risk of Overall Cancer’ in 13 out of 14 TypesGastrointestinal Effects of Incretin Obesity Drugs ExploredOzempic to Mounjaro - what are the weight loss injections and what were they designed to do?

Obesity is a major contributor to various chronic health conditions, including Type 2 diabetes, heart disease, and certain cancers. Thorpe's research indicates that even a modest weight loss of 5% can lead to significant reductions in healthcare spending—up to $1,262 annually for Medicare beneficiaries. He argues that the potential savings from covering weight loss drugs could outweigh the initial costs, which are estimated to reach $85 million in fiscal year 2025-26 and $680 million by 2028-29.

Calmatters

A recent study published in JAMA Oncology found that individuals taking GLP-1 receptor agonists, such as Ozempic and Wegovy, had a 17% lower risk of developing cancer compared to non-users. This suggests that these medications not only assist in weight loss but may also play a role in reducing cancer risk, particularly for obesity-related cancers.

Cancer Risk Declines With Use of Ozempic and Zepbound– New Study Shows Weightloss Drugs Linked to ‘Reduced Risk of Overall Cancer’ in 13 out of 14 TypesOzempic to Mounjaro - what are the weight loss injections and what were they designed to do?Gastrointestinal Effects of Incretin Obesity Drugs Explored

Critics of the Medi-Cal cuts argue that the long-term costs associated with untreated obesity—estimated at nearly $90 billion in lost economic activity and over $10 billion in direct healthcare spending in California—far exceed the projected savings from the policy change. Thorpe emphasizes that continuing coverage for weight loss drugs is a prudent investment that could save approximately $3,000 per patient by preventing future health complications.

Calmatters

While prescription medications like Ozempic and Wegovy are designed to aid weight loss safely, the market is also flooded with over-the-counter (OTC) weight loss supplements, which can pose serious health risks. Reports indicate that these supplements lead to over 23,000 emergency room visits annually in the U.S. due to adverse effects, including severe health complications. Many OTC products contain harmful stimulants and unregulated ingredients, raising concerns about their safety and efficacy.

The hidden dangers of over-the-counter weight-loss supplements

The decision to limit Medi-Cal coverage for weight loss drugs raises critical questions about the state's approach to obesity management. As obesity continues to be a significant public health challenge, the implications of this policy could affect not only individual health outcomes but also broader healthcare costs. Policymakers are urged to consider the long-term benefits of investing in effective obesity treatments, including GLP-1 receptor agonists, to mitigate the risks associated with untreated obesity.

Calmatters